Adjuvant therapy for older women breast cancer

Breast

Volumn 12, Issue 6, 2003, Pages 550-557

  Muss, H B ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Adjuvant therapy; Age; Elderly; Older

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTHRITIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DEVELOPED COUNTRY; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; GROUPS BY AGE; HEART DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; LIFE EXPECTANCY; META ANALYSIS; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VAGINA BLEEDING; VAGINA DISCHARGE; VEIN THROMBOSIS;

EID: 0348149057     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00165-6     Document Type: Article

References (34)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. La Vecchia C, Lucchini F, Negri E, Levi F. Cancer mortality in the elderly, 1960-1998: a worldwide approach. Oncol Spectrums 2001; 2: 386-394.
3. Yancik R, Wesley M N, Ries L A, Havlik R J, Edwards B K, Yates J W. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892.
4. Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology 2001; 15: 1567-1580.
5. Extermann M, Overcash J, Lyman G H, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
6. Satariano W A, Ragland D R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-110.
7. Welch H G, Albertsen P C, Nease R F, Bubolz T A, Wasson J H. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996; 124: 577-584.
8. Extermann M, Balducci L, Lyman G H. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18: 1709-1717.
9. Anonymous. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-942.
10. Anonymous. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 1998; 351: 1451-1467.
11. Diab S G, Elledge R M, Clark G M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92: 550-556.
12. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
13. Winer E P, Hudis C, Burstein H J et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20: 3317-3327.
14. Christman K, Muss H B, Case L D, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA 1992; 268: 57-62.
15. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18: 1412-1422.
16. Gelman R S, Taylor S G. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2: 1404-1413.
17. Du X L, Osborne C, Goodwin J S. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002; 20: 4636-4642.
18. Ibrahim N K, Hortobagyi G N, Ewer M et al. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol 1999; 43: 471-478.
19. Dees E C, O'Reilly S, Goodman S N et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18: 521-529.
20. Kimmick G G, Shelton B J, Case L D, Cooper M R, Muss H B. Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. Breast Cancer Res Treat 2002; 72: 233-243.
21. Fargeot P, Roche H, Bonneterre J M et al. Disease-free survival (DES) advantage of weekly epirubicin plus tamoxifen vs tamoxifen (Tam) alone as adjuvant treatment of operable, node-positive (N +) elderly breast cancer (BC) patient (Pts): 5-year follow-up results of French Adjuvant Study Group, FASG-08 Trial [abstract]. Proc Am Soc Clin Oncol 2002; 21: 37a.
22. Fisher B, Jeong J H, Byrant J, Mamounas E P et al. Findings from two decades of national surgical adjuvant breast and bowel project clinical trials involving breast cancer patients with negative axillary nodes [abstract]. Breast Cancer Res Treat 2002; 76(Suppl) 1: S32.
23. Desch C E, Hillner B E, Smith T J, Retchin S M. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993; 11: 777-782.
24. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241.
25. Truong P T, Bernstein V, Speers C, Olivotto I A. Omission of radiotherapy after breast conserving surgery adversely impacts survival in elderly women [abstract]. Breast Cancer Res Treat 2002; 76: 36.
26. Hughes K S, Schnaper L A, Berry D et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER + ) breast carcinoma [abstract]. Proc Am Soc Clin Oncol 2001; 20: 24a.
27. Fisher B, Jeong J H, Dignam J et al. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; 62-66.
28. Whelan T J, Julian J, Wright J, Jadad A R, Levine M L. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000; 18: 1220-1229.
29. Trimble E L, Carter C L, Cain D, Freidlin B, Ungerleider R S, Friedman M A. Representation of older patients in cancer treatment trials. Cancer 1994; 74: 2208-2214.
30. Hutchins L F, Unger J M, Crowley J J, Coltman Jr. C A, Albain K S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
31. Sateren W B, Trimble E L, Abrams J, Brawley O, Breen N et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002; 20: 2109-2117.
32. Siminoff L A, Zhang A, Saunders Sturm C M, Colabianchi N. Referral of breast cancer patients to medical oncologists after initial surgical management [see comments]. Med Care 2000; 38: 696-704.
33. Kemeny M, Muss H B, Kornblith A B, Peterson B, Wheeler J, Cohen H J. Barriers to participation of older women with breast cancer in clinical trials [abstract]. Proc Am Soc Clin Oncol 2000; 19: 602a.
34. Lara Jr. P N, Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728-1733.